Remember when drugmakers were growth stocks? If you wanted to track down juicy yields, you were better served by turning to utility or financial stocks. Not anymore. You wouldn't believe the kind of fat payouts being generated by the major pharmaceutical companies.

Company

Dividend Yield

Johnson & Johnson (NYSE:JNJ)

2.5%

Bristol-Myers Squibb (NYSE:BMY)

3.8%

Pfizer (NYSE:PFE)

4.5%

Merck (NYSE:MRK)

2.8%

GlaxoSmithKline (NYSE:GSK)

3.7%

Eli Lilly (NYSE:LLY)

2.9%

Wyeth (NYSE:WYE)

2.4%

It's no surprise that three of those seven companies have made the cut in the Income Investor newsletter service. High income and recession-resistant stock plays? Yum.

Unfortunately, it hasn't been all dividends and dependability in the drug sector. Many key players have become market laggards. More importantly, we can't get two Fools to agree on the prospects of one of the industry's biggest stars: Johnson & Johnson.

Ryan Fuhrmann is bullish this week. Billy Fisher returns as our bear. Where do you stand when it comes to Johnson & Johnson? That's what this week's bout is all about.

Duel on!

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.